drugset / Trial / NCT04850846
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Phase 2
Active not recruiting
60 enrolled
Dana-Farber Cancer Institute
National Cancer Institute (NCI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved in this study is: * Metformin, extended release * Placebo ( a pill that has no active ingredients)
Timeline
- Start
- 2021-04-27
- Primary completion
- 2025-01-29
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 1500 mg | Oral |